Current and projected future economic burden of Parkinson’s disease in the U.S.

Abstract Parkinson’s disease (PD) is one of the world’s fastest growing neurological disorders. Much is unknown about PD-associated economic burdens in the United States (U.S.) and other high-income nations. This study provides a comprehensive analysis of the economic burdens of PD in the U.S. (2017) and projections for the next two decades. Multiple data sources were used to estimate the costs of PD, including public and private administrative claims data, Medicare Current Beneficiary Survey, Medical Expenditure Panel Survey, and a primary survey ( n = 4,548) designed for this study. We estimated a U.S. prevalence of approximately one million individuals with diagnosed Parkinson’s disease in 2017 and a total…

• MJ
  Michael J. Fox Foundation for Parkinson's Research
• B
  Biogen
• AP
  American Parkinson Disease Association
• A
  AbbVie
• UO
  University of Pennsylvania
• PA
  Parkinson Alliance
• PF
  Parkinson's Foundation
• AP
  ACADIA Pharmaceuticals
• AT
  Acorda Therapeutics
• AP
  Adamas Pharmaceuticals
• UO
  University of Toronto
• PS
  Perelman School of Medicine, University of Pennsylvania